A
71.98
1.14 (1.61%)
| Previous Close | 70.84 |
| Open | 71.87 |
| Volume | 1,039,317 |
| Avg. Volume (3M) | 779,700 |
| Market Cap | 4,162,090,496 |
| Price / Sales | 99.79 |
| Price / Book | 8.49 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -211.46% |
| Operating Margin (TTM) | -847.56% |
| Diluted EPS (TTM) | -2.99 |
| Quarterly Revenue Growth (YOY) | -79.30% |
| Total Debt/Equity (MRQ) | 12.76% |
| Current Ratio (MRQ) | 4.93 |
| Operating Cash Flow (TTM) | -114.70 M |
| Levered Free Cash Flow (TTM) | -10.43 M |
| Return on Assets (TTM) | -16.69% |
| Return on Equity (TTM) | -35.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Arcellx, Inc. | Bearish | Bullish |
AIStockmoo Score
1.1
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 1.13 |
|
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 14.50% |
| % Held by Institutions | 102.08% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Aju Ib Investment Co., Ltd. | 30 Sep 2025 | 1,047,557 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 130.00 (Canaccord Genuity, 80.61%) | Buy |
| Median | 117.00 (62.55%) | |
| Low | 88.00 (Cantor Fitzgerald, 22.26%) | Hold |
| Average | 113.00 (56.99%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 81.35 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Canaccord Genuity | 08 Dec 2025 | 130.00 (80.61%) | Buy | 74.08 |
| 03 Nov 2025 | 130.00 (80.61%) | Buy | 86.13 | |
| Needham | 08 Dec 2025 | 105.00 (45.87%) | Buy | 74.08 |
| Stifel | 16 Oct 2025 | 129.00 (79.22%) | Buy | 88.85 |
| Cantor Fitzgerald | 09 Oct 2025 | 88.00 (22.26%) | Hold | 88.39 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Dec 2025 | Announcement | Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma |
| 18 Nov 2025 | Announcement | Arcellx to Host Investor Relations Event During the 67th ASH Annual Meeting and Exposition |
| 05 Nov 2025 | Announcement | Arcellx Provides Third Quarter 2025 Financial Results |
| 03 Nov 2025 | Announcement | Arcellx to Present New Data for Its iMMagine-1 Study and Continues Scientific Momentum with Multiple Presentations at the 67th ASH Annual Meeting and Exposition |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |